Ziprasidone
- TRADE NAME: Geodon (Pfizer)
- INDICATIONS: Schizophrenia, bipolar I disorder
- CLASS: Antipsychotic
- HALF-LIFE: 7 hours
Acetylcholinesterase inhibitors, Alcohol, Alfuzosin, Amitriptyline, Amoxapine, Amphetamines, Antifungals, Arsenic, Artemether/Lumefantrine, Asenapine, Astemizole, Carbamazepine, Chloroquine, Ciprofloxacin, Citalopram, CNS depressants, Conivaptan, Dasatinib, Degarelix, Dolasetron, Dopamine agonists, Dopamine agonists, Dronedarone, Food, Gadobutrol, Ketoconazole, Lapatinib, Levodopa, Levofloxacin, Lithium, Methylphenidate, Metoclopramide, Moxifloxacin, Nilotinib, Pazopanib, Pimavanserin, Pimozide, QT prolonging agents, Quinagolide, Quinine, Ranolazine, St John's Wort, Telavancin, Telithromycin, Tetrabenazine, Thioridazine, Voriconazole, Vorinostat
PREGNANCY CATEGORY: C
Ziprasidone should be avoided in patients with congenital long QT syndrome or a history of cardiac arrhythmias.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ziprasidone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
